**Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO-1 and PSO-2 trials**

Diamant Thaci,1 Mark Lebwohl,2 Richard B. Warren,3 Leon Kirck,4 Subhashis Banerjee,5 Andrew Napoli,6 Renata M. Kisa,7 Misti Linaberry,8 Kim Hoyt,9 Andrew Blauvelt5

1Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany; 2Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3Dermatology Centre, Northern Care Alliance NHS Foundation Trust, NHIR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; 4Bristol Myers Squibb, Princeton, NJ, USA; 5Oregon Medical Research Center, Portland, OR, USA

**Synopsis**

- **Objective**: Randomized adults with moderate to severe plaque psoriasis 1:2:1 to oral deucravacitinib 3 mg QD or 6 mg QD or placebo for 52 weeks, then continuous deucravacitinib 3 mg QD or 6 mg QD or placebo for 112 more weeks.

**Efficacy**

- **Primary endpoint**: PASI 75 (≥75% reduction from baseline) at Week 112.

- **Statistical analysis**: mNRI, TFR, and bootstrap methods.

**Conclusions**

- Continuous treatment with deucravacitinib improves PASI 75/90 responses and sPGA 0/1 in patients with moderate to severe plaque psoriasis.

---

**Efficacy population**

- **Efficacy population**: POETYK PSO-1 and PSO-2 patient populations.

- **Analysis**: Week 112 responders who received continuous deucravacitinib treatment from Week 1 to Week 112.

- **Week of enrollment**: Week 0 or Week 52.

**Efficacy outcomes**

- **Improvement of ≥2-point reduction from baseline in PASI (≥90%)**
- **sPGA 0/1**

**Results**

- **Baseline patient demographics and disease characteristics**
- **401 of 513 patients received continuous deucravacitinib treatment from baseline until Week 112**

**Figure 2. POETYK PSO-1, PSO-2, and LTE analysis populations**

**Table 1. Baseline patient demographics and disease characteristics**

**Figure 3. PASI 90 response rates in patients who received continuous deucravacitinib treatment from baseline until Week 112**

**Figure 4. PASI 75 response rates in patients who received continuous deucravacitinib treatment from baseline until Week 112**

**Figure 5. sPGA 0/1 response rates in patients who received continuous deucravacitinib treatment from baseline until Week 112**

---

**References**
